Professor of Medicine, Boston University
Internal Medicine
Dr. Elaine M. Hylek, MD
|
|
Give Review
Elaine Hylek works in the field of Internal Medicine. She went to University of Pittsburgh School of Medicine. She has 2 awards "Patient-Centered Medical Home Recognition Program" and "Boston Magazine". Elaine Hylek is a published doctor. She has 99 papers published. The most current publication "Who, when, and how to reverse non-vitamin K oral anticoagulants." She accepts all Medicare patients.
Publications
- Who, when, and how to reverse non-vitamin K oral anticoagulants.
- Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage.
- Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial...
- Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial.
- Management and clinical outcomes in patients treated with apixaban versus warfarin undergoing procedures.
- Age-related changes in thrombosis and hemostasis.
- Anticoagulation in the Older Adult: Optimizing Benefit and Reducing Risk.
- Biomarkers in Lone Atrial Fibrillation-An Additional 'Fine Tuning' of Risk?
- Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Bette...
- Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Even...
- Stratifying the Risks of Oral Anticoagulation in Patients With Liver Disease.
- National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation.
- Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of At...
- Explaining Racial Disparities in Anticoagulation Control: Results From a Study of Patients at the Veterans Administration.
- Female sex as an independent risk factor for stroke in atrial fibrillation: Possible mechanisms.
- Outcomes of Anticoagulation Therapy in Patients with Mental Health Conditions.
- Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation.
- Comparing patient-level and site-level anticoagulation control as predictors of adverse events.
- Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes.
- Antiplatelet therapy in prevention of cardio- and venous thromboembolic events.
- Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembol...
- Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better ...
- Obesity begets atrial fibrillation: a contemporary summary.
- Venous thromboembolism after joint replacement in older male veterans with comorbidity.
- Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.
- Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.
- Anticoagulation therapy for atrial fibrillation.
- Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence.
- Comparison of ischemic stroke outcomes and patient and hospital characteristics by race/ethnicity and socioeconomic status.
- Identifying major hemorrhage with automated data: results of the veterans affairs study to improve anticoagulation (VARIA).
- INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).
- Warfarin and acetaminophen interaction: a summary of the evidence and biological plausibility.
- Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF.
- Stroke Prevention in Atrial Fibrillation: Current Status and Near-Future Directions.
- The Business Case for Quality Improvement: Oral Anticoagulation for Atrial Fibrillation.
- American Heart Association Atrial Fibrillation Research Summit: A Conference Report From the American Heart Association.
- Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
- Prompt Repeat Testing After Out-of-Range INR Values: A Quality Indicator for Anticoagulation Care.
- Relevance of current guidelines for organizing an anticoagulation clinic.
- Re-Examining the Recommended Follow-Up Interval after an In-Range INR Value: Results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).
- Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagul...
- Therapeutic potential of oral factor Xa inhibitors.
- Bleeding risk on warfarin among elderly patients with atrial fibrillation.
- Epidemiology of subtherapeutic anticoagulation in the United States.
- Antithrombotic prophylaxis in elderly patients with atrial fibrillation.
- The need for new oral anticoagulants in clinical practice.
- Measuring quality of oral anticoagulation care: extending quality measurement to a new field.
- Clopidogrel, genetics, and drug responsiveness.
- Atrial fibrillation and stroke severity: expanding the mechanistic exemplar, clinical phenotype, and goals of anticoagulant pharmacotherapy.
- Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III vers...
- The representation of women on the editorial boards of major medical journals: a 35-year perspective.
- Genetic testing for warfarin dosing? Not yet ready for prime time.
- Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination.
- Risk of thromboembolism with short-term interruption of warfarin therapy.
- Oral anticoagulant therapy for patients with atrial fibrillation--an update.
- Death and disability from warfarin-associated intracranial and extracranial hemorrhages.
- Effectiveness of warfarin among patients with cancer.
- The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation.
- Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
- Response to Letter by Testa et al.
- Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.
- The "gender gap" in authorship of academic medical literature--a 35-year perspective.
- Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation.
- The risk of hemorrhage among patients with warfarin-associated coagulopathy.
- Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force.
- Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) s...
- Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population.
- Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.
- Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
- Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
- Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors.
- Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis.
- DU-176b, an oral, direct Factor Xa antagonist.
- Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation.
- The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
- Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycle.
- Warfarin for atrial fibrillation in community-based practise.
- Warfarin dose management affects INR control.
- Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician.
- Outcomes and predictors of very stable INR control during chronic anticoagulation therapy.
- Warfarin pharmacogenetics.
- Understanding low INR in clinical practice.
- Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil.
- Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis.
- Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Socie...
- Brand name versus generic warfarin: a systematic review of the literature.
- Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.
- Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
- Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users.
- Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).
- High blood pressure while taking antithrombotic medication is associated with an increased risk of developing intracranial haemorrhage.
- New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs.
- Anticoagulation for valvular heart disease in community-based practice.
- Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy.
- Reducing the risk for stroke in patients who have atrial fibrillation.
- Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum.
- Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
- Contra: ''Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation''. Caveats regarding use of oral anticoagulant ther...
Schools
University of Pittsburgh School of Medicine
Mass General Hospital
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- Patient-Centered Medical Home Recognition Program
- Boston Magazine
Education
-
Massachusetts General Hospital -
University of Pittsburgh School of Medicine
Hospital
-
Boston Medical Center
Drug Facts
| NPI NUMBER | 1851359954 | |
| NPPES Provider LastName | HYLEK | |
| NPPES Provider FirstName | ELAINE | |
| NPPES Provider ZIPCode | 021182526 | |
| NPPES Provider State | MA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 6199.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 36.0 | |
| Percent Opioid Claims | 0.58 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851359954 |
| Last Name Of The Provider | HYLEK |
| First Name Of The Provider | ELAINE |
| View All |
Similar Doctors
|
|
Dr. Varsha K. Tanguturi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aditya Mandawat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph W. Franses, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine T. Steele, MD |
|
|
Dr. Sandra R. Richman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bhavna Lall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth H. Stover, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan W. Gwyn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erika H. Riley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter J. Leahy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Denise H. Tam, MD
This Doctor is OpenDoctor Recommended.
|